This is designed as a randomized, double-blind, placebo-controlled clinical trial with a 12
week intervention period. Seventy participants with a diagnosis of AD, vascular, and mixed
dementia with at least 3 behavioral symptoms present from the Neuropsychiatric Inventory
Questionnaires (NPI-Q) will be randomized to the Feru-guard (ferulic acid and Angelica
archangelica) or placebo group. Participants will be screened first by a telephone interview
or briefly in-clinic and then will be scheduled for an in-clinic screen to establish study
eligibility prior to the baseline assessment visit. Clinical and biological outcome measures
will occur at baseline and 12 weeks.